胰高血糖素样肽-1受体激动剂在NAFLD管理中的新兴作用
本文综述了非酒精性脂肪性肝病(NAFLD)相关肝硬化负担日益加重,内分泌科医生在肥胖或2型糖尿病(T2D)成人中常漏诊。近期研究显示胰高血糖素样肽-1受体激动剂(GLP-1RAs)对该人群的非酒精性脂肪性肝炎(NASH)有益,2021年FDA批准司美格鲁肽用于肥胖管理,提示管理范式正在转变。
要点
- 内分泌科医生应主导多学科团队,对肥胖、糖尿病前期或T2D高危人群筛查临床显著纤维化。
- 目前无FDA批准NAFLD药物,减重是管理核心,可用维生素E(非T2D者)或吡格列酮/GLP-1RA。
- GLP-1RAs在活检证实的NASH成人中获益已获证实,司美格鲁肽2021年获批用于肥胖管理。
核心结论
- 内分泌科医生对NAFLD的认识提高与更广泛使用GLP-1RAs的新临床路径正在形成范式转变。
研究设计与样本
- 本小型综述基于观察性研究、随机对照试验和荟萃分析证据,旨在帮助内分泌科医生识别NAFLD/NASH并了解GLP-1RAs的作用。
主要发现
- 近期试验证实GLP-1RAs在活检证实的NASH成人中具有获益。
- 2021年FDA批准司美格鲁肽用于肥胖管理。
- 目前无FDA批准用于NAFLD的药物,减重是成功管理的核心。
关键数值与推荐
- 近期共识声明呼吁筛查和治疗临床显著纤维化以预防肝硬化,尤其在高危人群(肥胖、糖尿病前期或T2D)中。
- 当前药物治疗选择限于维生素E(用于非T2D人群)和可逆转脂肪性肝炎的糖尿病药物如吡格列酮或GLP-1RA。
临床怎么用
- 内分泌科医生应领导多学科团队实施NAFLD共识声明,对高危人群筛查临床显著纤维化。
- 在肥胖或T2D合并NAFLD/NASH成人中可考虑使用GLP-1RAs。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The burden of cirrhosis from nonalcoholic fatty liver disease (NAFLD) is reaching epidemic proportions in the United States. This calls for greater awareness among endocrinologists, who often see but may miss the diagnosis in adults with obesity or type 2 diabetes mellitus (T2D) who are at the highest risk. At the same time, recent studies suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs) are beneficial vs nonalcoholic steatohepatitis (NASH) in this population. This minireview aims to assist endocrinologists to recognize the condition and recent work on the role of GLP-1RAs in NAFLD/NASH. EVIDENCE ACQUISITION: Evidence from observational studies, randomized controlled trials, and meta-analyses. EVIDENCE SYNTHESIS: Endocrinologists should lead multidisciplinary teams to implement recent consensus statements on NAFLD that call for screening and treatment of clinically significant fibrosis to prevent cirrhosis, especially in the high-risk groups (ie, people with obesity, prediabetes, or T2D). With no US Food and Drug Administration (FDA)-approved agents, weight loss is central to successful management, with pharmacological treatment options limited today to vitamin E (in people without T2D) and diabetes medications that reverse steatohepatitis, such as pioglitazone or GLP-1RA. Recently, the benefit of GLP-1RAs in NAFLD, suggested from earlier trials, has been confirmed in adults with biopsy-proven NASH. In 2021, the FDA also approved semaglutide for obesity management. CONCLUSION: A paradigm change is developing between the endocrinologist's greater awareness about their critical role to curve the epidemic of NAFLD and new clinical care pathways that include a broader use of GLP-1RAs in the management of these complex patients.
引用
- Patel Chavez C, Cusi K, Kadiyala S, et al. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab. 2022. PMID: 34406410. doi:10.1210/clinem/dgab578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。